References
- Nieves DJ, Heininger U. Bordetella pertussis. Microbiol Spectr. 2016;4(3): 1–21 DOI: https://doi.org/10.1128/microbiolspec.EI10-0008-2015
- Moore A, Harnden A, Grant CC, et al. Clinically diagnosing pertussis-associated cough in adults and children: CHEST guideline and expert panel report. Chest. 2019;155(1):147–154. DOI:https://doi.org/10.1016/j.chest.2018.09.027
- Lee GM, Lett S, Schauer S, Massachusetts Pertussis Study Group, et al. Societal costs and morbidity of pertussis in adolescents and adults. Clin Infect Dis. 2004;39(11):1572–1580. DOI:https://doi.org/10.1086/425006
- De Serres G, Shadmani R, Duval B, et al. Morbidity of pertussis in adolescents and adults. J Infect Dis. 2000;182(1):174–179. DOI:https://doi.org/10.1086/315648
- van Hoek AJ, Campbell H, Andrews N, et al. The burden of disease and health care use among pertussis cases in school aged children and adults in England and Wales; a patient survey. PLoS One. 2014;9(11):e111807 DOI:https://doi.org/10.1371/journal.pone.0111807
- Zambrano JA, Herman TN. Rib fracture associated with Bordetella pertussis infection. N Engl J Med. 2018;378(3):e4. DOI:https://doi.org/10.1056/NEJMicm1701940
- Clarke MF, Rasiah K, Copland J, et al. The pertussis epidemic: informing strategies for prevention of severe disease. Epidemiol Infect. 2013;141(3):463–471. DOI:https://doi.org/10.1017/S095026881200091X
- Liu BC, McIntyre P, Kaldor JM, et al. Pertussis in older adults: prospective study of risk factors and morbidity. Clin Infect Dis. 2012;55(11):1450–1456. DOI:https://doi.org/10.1093/cid/cis627
- Skoff TH, Hadler S, Hariri S. The epidemiology of nationally reported pertussis in the United States, 2000-2016. Clin Infect Dis. 2019;68(10):1634–1640. DOI:https://doi.org/10.1093/cid/ciy757
- Karki S, McIntyre P, Newall AT, et al. Risk factors for pertussis hospitalizations in Australians aged 45 years and over: a population based nested case-control study. Vaccine. 2015;33(42):5647–5653. DOI:https://doi.org/10.1016/j.vaccine.2015.08.068
- McGuiness CB, Hill J, Fonseca E, et al. The disease burden of pertussis in adults 50 years old and older in the United States: a retrospective study. BMC Infect Dis. 2013; 13:32 DOI:https://doi.org/10.1186/1471-2334-13-32
- Leong RNF, Wood JG, Liu B, et al. High healthcare resource utilisation due to pertussis in Australian adults aged 65 years and over. Vaccine. 2020;38(19):3553–3559. DOI:https://doi.org/10.1016/j.vaccine.2020.03.021
- McGirr A, Fisman DN, Tuite AR. The health and economic burden of pertussis in Canada: a microsimulation study. Vaccine. 2019;37(49):7240–7247. DOI:https://doi.org/10.1016/j.vaccine.2019.09.070
- Public Health England [Internet]. Laboratory confirmed cases of pertussis in England: annual report for 2019 [cited 2020. Oct 21]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/881380/hpr0820_PRTSSS_annual.pdf.
- Public Health England [Internet]. Laboratory confirmed cases of pertussis in England. Annual report for 2019 supplementary data tables [cited 2020 Nov 20]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/881410/Laboratory_confirmed_cases_of_pertussis_in_England_2019.pdf.
- Rønn PF, Dalby T, Simonsen J, et al. Seroepidemiology of pertussis in a cross-sectional study of an adult general population in Denmark. Epidemiol Infect. 2014;142(4):729–737. DOI:https://doi.org/10.1017/S0950268813002446
- Jõgi P, Oona M, Toompere K, et al. Estimated and reported incidence of pertussis in Estonian adults: A seroepidemiological study. Vaccine. 2015;33(38):4756–4761. DOI:https://doi.org/10.1016/j.vaccine.2015.08.007
- de Melker HE, Versteegh FG, Schellekens JF, et al. The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys. J Infect. 2006;53(2):106–113. DOI:https://doi.org/10.1016/j.jinf.2005.10.020
- GBD Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2020;8(6):585–596.
- Rayner L, Sherlock J, Creagh-Brown B, et al. The prevalence of COPD in England: An ontological approach to case detection in primary care. Respir Med. 2017; 132:217–225. DOI:https://doi.org/10.1016/j.rmed.2017.10.024
- Buck PO, Meyers JL, Gordon LD, et al. Economic burden of diagnosed pertussis among individuals with asthma or chronic obstructive pulmonary disease in the USA: an analysis of administrative claims. Epidemiol Infect. 2017;145(10):2109–2121. DOI:https://doi.org/10.1017/S0950268817000887
- Mukherjee P, Cheuvart B, Baudson N, et al. Seroprevalence of Bordetella pertussis in chronic obstructive pulmonary disease (COPD) patients [abstract]. Eur Respir J. 2020;56(suppl. 64):4927. DOI: https://doi.org/10.1183/13993003.congress-2020.4927.
- Mbayei SA, Faulkner A, Miner C, et al. Severe Pertussis Infections in the United States, 2011–2015. Clin Infect Dis. 2019;69(2):218–226. DOI:https://doi.org/10.1093/cid/ciy889
- Ward BW, Nugent CN, Blumberg SJ, et al. Measuring the prevalence of diagnosed chronic obstructive pulmonary disease in the United States using data from the 2012–2014 National Health Interview Survey. Public Health Rep. 2017;132(2):149–156. DOI:https://doi.org/10.1177/0033354916688197
- Jenkins VA, Savic M, Kandeil W. Pertussis in high-risk groups: an overview of the past quarter-century. Hum Vaccin Immunother. 2020;16(11):2609–2617. DOI: https://doi.org/10.1080/21645515.2020.1738168.
- Blasi F, Bonanni P, Braido F, et al. The unmet need for pertussis prevention in patients with chronic obstructive pulmonary disease in the Italian context. Hum Vaccin Immunother. 2020;16(2):340–348. DOI:https://doi.org/10.1080/21645515.2019.1652517
- Global Initiative for Chronic Obstructive Lung Disease [Internet]. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonar disease [cited 2020 Nov 20]. Available from: https://goldcopd.org/2021-gold-reports/.
- Punekar YS, Shukla A, Mullerova H. COPD management costs according to the frequency of COPD exacerbations in UK primary care. Int J Chron Obstruct Pulmon Dis. 2014; 9:65–73. DOI:https://doi.org/10.2147/COPD.S54417
- Ghobadi H, Ahari SS, Kameli A, et al. The relationship between COPD assessment test (CAT) scores and severity of airflow obstruction in stable COPD patients. Tanaffos. 2012;11(2):22–26.
- Rebordosa C, Plana E, Aguado J, et al. GOLD assessment of COPD severity in the Clinical Practice Research Datalink (CPRD). Pharmacoepidemiol Drug Saf. 2019;28(2):126–133. DOI:https://doi.org/10.1002/pds.4448
- Curtis L, Burns A. [Internet]. Unit costs of health and social care 2019 [cited 2020 Dec 18]. Available from: https://www.pssru.ac.uk/project-pages/unit-costs/unit-costs-2019/.
- National Health Service (NHS) [Internet]. Amendments to the drug tariff. September 2019 [cited 2020 Mar 26]. Available from: https://www.nhsbsa.nhs.uk/sites/default/files/2019-08/Drug%20Tariff%20September%202019.pdf.
- National Health Service (NHS) [Internet]. National cost collection for the NHS [cited 2020 Mar 26]. Available from: https://www.england.nhs.uk/national-cost-collection/#ncc1819.
- Barker J. Interactive complexity and comorbidity splits in Health Resource Group 4+. Brit J Healthcare Manage. 2015;21(9):433–439. DOI:https://doi.org/10.12968/bjhc.2015.21.9.433
- National Health Service (NHS) [Internet]. Costing grouper [cited 2020 Mar 26]. Available from: https://digital.nhs.uk/services/national-casemix-office/downloads-groupers-and-tools/costing–-hrg4-2018-19-reference-costs-grouper.
- Weir S, Samnaliev M, Kuo TC, et al. The incidence and healthcare costs of persistent postoperative pain following lumbar spine surgery in the UK: a cohort study using the Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES). BMJ Open. 2017;7(9):e017585 DOI:https://doi.org/10.1136/bmjopen-2017-017585
- Ulm K. A simple method to calculate the confidence interval of a standardized mortality ratio (SMR). Am J Epidemiol. 1990;131(2):373–375. DOI:https://doi.org/10.1093/oxfordjournals.aje.a115507
- Kurz CF. Tweedie distributions for fitting semicontinuous health care utilization cost data. BMC Med Res Methodol. 2017;17(1):171–178. DOI:https://doi.org/10.1186/s12874-017-0445-y
- Aris E, Akpo EI, Bhavsar A, et al. Burden of pertussis in COPD: a retrospective database study in England [abstract]. Eur Respir J. 2020;56 (suppl.64):2468. DOI:https://doi.org/10.1183/13993003.congress-2020.2468.
- Kandeil W, Atanasov P, Avramioti D, et al. The burden of pertussis in older adults: what is the role of vaccination? A systematic literature review. Expert Rev Vaccines. 2019;18(5):439–455. DOI:https://doi.org/10.1080/14760584.2019.1588727
- Meier GC, Watkins J, McEwan P, et al. Resource use and direct medical costs of acute respiratory illness in the UK based on linked primary and secondary care records from 2001 to 2009. PLoS One. 2020;15(8):e0236472 DOI:https://doi.org/10.1371/journal.pone.0236472
- Mallia P, Message SD, Gielen V, et al. Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. Am J Respir Crit Care Med. 2011;183(6):734–742. DOI:https://doi.org/10.1164/rccm.201006-0833OC
- Sethi S. Infection as a comorbidity of COPD. Eur Respir J. 2010;35(6):1209–1215. DOI:https://doi.org/10.1183/09031936.00081409
- Centers for Disease Control and Prevention (CDC) [Internet]. Lung disease including asthma and adult vaccination [cited 2020 Nov 5]. Available from: https://www.cdc.gov/vaccines/adults/rec-vac/health-conditions/lung-disease.html.
- Centers for Disease Control and Prevention (CDC) [Internet]. Adult immunization schedule [cited 2020 Aug 19]. Available from: https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html.
- Centers for Disease Control and Prevention (CDC) [Internet]. Vaccination coverage among adults in the United States, National Health Interview Survey, 2017. [cited 2020 Nov 5]. Available from: https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/pubs-resources/NHIS-2017.html.
- Boey L, Bosmans E, Ferreira LB, et al. Vaccination coverage of recommended vaccines and determinants of vaccination in at-risk groups. Hum Vaccin Immunother. 2020;16(9):2136–2143. DOI:https://doi.org/10.1080/21645515.2020.1763739
- National Health Service (NHS) [Internet]. Flu vaccine [cited 2020 Nov 5]. Available from: https://www.nhs.uk/conditions/vaccinations/flu-influenza-vaccine/.
- National Health Service (NHS) [Internet]. Who should have the pneumococcal vaccine? [cited 2020 Nov 5]. Available from: https://www.nhs.uk/conditions/vaccinations/when-is-pneumococcal-vaccine-needed/.
- National Health Service (NHS) [Internet]. Whooping cough [cited 2021 Jan 21]. Available from: https://www.nhs.uk/conditions/whooping-cough/.
- Van Damme P, McIntyre P, Grimprel E, et al. Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix®) in adults 55 years of age and over: a sub-analysis of four trials. Vaccine. 2011;29(35):5932–5939. DOI:https://doi.org/10.1016/j.vaccine.2011.06.049
- Weston WM, Friedland LR, Wu X, et al. Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix(®)): results of two randomized trials. Vaccine. 2012;30(9):1721–1728. DOI:https://doi.org/10.1016/j.vaccine.2011.12.055
- Liu BC, He WQ, Newall AT, et al. Effectiveness of acellular pertussis vaccine in older adults: Nested matched case-control study. Clin Infect Dis. 2020;71(2):340–350. DOI:https://doi.org/10.1093/cid/ciz821
- Leidner AJ, Murthy N, Chesson HW, et al. Cost-effectiveness of adult vaccinations: a systematic review. Vaccine. 2019;37(2):226–234. DOI:https://doi.org/10.1016/j.vaccine.2018.11.056
- Kamiya H, Cho BH, Messonnier ML, et al. Impact and cost-effectiveness of a second tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine dose to prevent pertussis in the United States. Vaccine. 2016;34(15):1832–1838. DOI:https://doi.org/10.1016/j.vaccine.2016.02.027
- Lee GM, Murphy TV, Lett S, et al. Cost effectiveness of pertussis vaccination in adults. Am J Prev Med. 2007;32(3):186–193. DOI:https://doi.org/10.1016/j.amepre.2006.10.016
- McGarry LJ, Krishnarajah G, Hill G, et al. Cost-effectiveness analysis of Tdap in the prevention of pertussis in the elderly. PLoS One. 2013;8(9):e67260 DOI:https://doi.org/10.1371/journal.pone.0067260
- van Hoek AJ, Campbell H, Amirthalingam G, et al. Cost-effectiveness and programmatic benefits of maternal vaccination against pertussis in England. J Infect. 2016;73(1):28–37. DOI:https://doi.org/10.1016/j.jinf.2016.04.012
- Lee GM, Riffelmann M, Wirsing von Konig CH. Cost-effectiveness of adult pertussis vaccination in Germany. Vaccine. 2008;26(29-30):3673–3679. DOI:https://doi.org/10.1016/j.vaccine.2008.04.068
- National Health Service [Internet]. 2017/18 Reference Costs [cited 26 Mar 2020]. Available from: https://improvement.nhs.uk/resources/reference-costs/
- National Health Service [Internet]. 2017/18 Reference Costs [cited 26 Mar 2020]. Available from: https://improvement.nhs.uk/resources/reference-costs/.